Tolerability and pharmacokinetic evaluation of inhaled dry powder tobramycin free base in non-cystic fibrosis bronchiectasis patients

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Hoppentocht, Marcel ^a   Akkerman, Onno W ^b   Hagedoorn, Paul ^a   Alffenaar, Jan Willem C ^b   Van Der Werf, Tjip S ^b   Kerstjens, Huib A M ^b   Frijlink, Henderik W ^a   De Boer, Anne H ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EXCIPIENT; TOBRAMYCIN; POWDER;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BRONCHIECTASIS; CLINICAL ARTICLE; COUGHING; DRUG MEGADOSE; DRUG TOLERABILITY; DRY POWDER; DRY POWDER INHALER; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; NON CYSTIC FIBROSIS BRONCHIECTASIS; SPIROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; BLOOD; COMPLICATION; CYSTIC FIBROSIS; DOSE RESPONSE; INHALATIONAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; POWDER;

ADMINISTRATION, INHALATION; ADULT; AGED; BRONCHIECTASIS; CYSTIC FIBROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRY POWDER INHALERS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; POWDERS; TOBRAMYCIN;

EID: 84962593768     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0149768     Document Type: Article

References (33)

1. Pappalettera M, Aliberti S, Castellotti P, Ruvolo L, Giunta V, Blasi F. Bronchiectasis: an update. Clin Respir J. Blackwell Publishing Ltd; 2009; 3: 126-134. doi: 10.1111/j.1752-699X.2009.00131.x
2. Angrill J, Agustí C, De Celis R, Filella X, Rañó A, Elena M, et al. Bronchial inflammation and colonization in patients with clinically stable bronchiectasis. Am J Respir Crit Care Med. American Thoracic SocietyNew York, NY; 2001; 164: 1628-32. doi: 10.1164/ajrccm.164.9.2105083
3. Altenburg J, de Graaff CS, van der Werf TS, Boersma WG. Immunomodulatory effects of macrolide antibiotics - part 1: biological mechanisms. Respiration. Karger Publishers; 2011; 81: 67-74. doi: 10.1159/000320319
4. Angrill J. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax. 2002; 57: 15-19. doi: 10.1136/thorax.57.1.15 PMID: 11809984
5. Nicotra MB. Clinical, Pathophysiologic, and Microbiologic Characterization of Bronchiectasis in an Aging Cohort. CHEST J. American College of Chest Physicians; 1995; 108: 955. doi: 10.1378/chest. 108.4.955
6. Ho P. The Effect of Pseudomonas aeruginosa Infection on Clinical Parameters in Steady-State Bronchiectasis. CHEST J. American College of Chest Physicians; 1998; 114: 1594. doi: 10.1378/chest.114. 6.1594
7. Miszkiel KA, Wells AU, Rubens MB, Cole PJ HD. Effects of airway infection by Pseudomonas aeruginosa: A computed tomographic study. Thorax. 1997; 52: 260-264. PMID: 9093343
8. Lynch DA, Newell J, Hale V, Dyer D, Corkery K, Fox NL, et al. Correlation of CT findings with clinical evaluations in 261 patients with symptomatic bronchiectasis. [Internet]. American Public Health Association; 2013. Available: http://www.ajronline.org/doi/abs/10.2214/ajr.173.1.10397099
9. Wilson CB, Jones PW, O'Leary CJ, Hansell DM, Cole PJ, Wilson R. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J. 1997; 10: 1754-1760. Available: http:// erj.ersjournals.com/content/10/8/1754.abstract PMID: 9272915
10. Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010; 65 Suppl 1: i1-58. doi: 10.1136/thx.2010.136119 PMID: 20627931
11. Maclusky IB, Gold R, Corey M, Levison H. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol. 1989; 7: 42-48. doi: 10.1002/ ppul.1950070110 PMID: 2505216
12. Smith AL, Ramsey BW, Hedges DL, Hack B, Williams-Warren J, Weber A, et al. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Pediatr Pulmonol. 1989; 7: 265-271. doi: 10.1002/ppul.1950070413 PMID: 2515523
13. Steinkamp G, Tümmler B, Gappa M, Von Der Hardt H, Potel J, Albus A, et al. Long-term tobramycin aerosol therapy in cystic fibrosis. Pediatr Pulmonol. 1989; 6: 91-98. doi: 10.1002/ppul.1950060207 PMID: 2494640
14. Vendrell M, Muñoz G, de Gracia J. Evidence of inhaled tobramycin in non-cystic fibrosis bronchiectasis. Open Respir Med J. 2015; 9: 30-6. doi: 10.2174/1874306401509010030 PMID: 25893022
15. Geller DE, Konstan MW, Smith J, Noonberg SB, Conrad C. Novel tobramycin inhalation powder in cystic fibrosis subjects: Pharmacokinetics and safety. Pediatr Pulm. Wiley Subscription Services, Inc., A Wiley Company; 2007; 42: 307-313. doi: 10.1002/ppul.20594
16. Hoppentocht M, Hagedoorn P, Frijlink HW, de Boer AH. Developments and strategies for inhaled antibiotic drugs in tuberculosis therapy: A critical evaluation. Eur J Pharm Biopharm. 2013; 86: 23-30. doi: 10.1016/j.ejpb.2013.10.019 PMID: 24189498
17. Hoppentocht M, Akkerman OW, Hagedoorn P, Frijlink HW, de Boer AH. The Cyclops for pulmonary delivery of aminoglycosides; a new member of the Twincer™family. Eur J Pharm Biopharm. 2015; 90: 8-15. doi: 10.1016/j.ejpb.2015.01.012 PMID: 25615881
18. TOBI Podhaler 28 mg inhalation powder, hard capsules - Summary of Product Characteristics (SPC) - (eMC) [Internet]. [cited 20 Mar 2015]. Available: http://www.medicines.org.uk/emc/medicine/24989/ SPC/TOBI+Podhaler+28+mg+inhalation+powder,+hard+capsules
19. Hoppentocht M, Akkeman OW, Voerman A, Greijdanus B, Touw DJ, Alffenaar JC. Optimisation of the sensitivity of an immunoassay analysis for tobramycin in serum. J Appl Bioanal. 2015; 1: 123-127. doi: 10.17145/jab.15.020
20. Proost JH, Meijer DKF. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med. 1992; 22: 155-163. doi: 10.1016/0010-4825 (92)90011-B PMID: 1617949
21. Konstan MW, Flume PA, Kappler M, Chiron R, Higgins M, Brockhaus F, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J Cyst Fibros. 2011; 10: 54-61. Available: http://www.sciencedirect.com/science/article/B6X2D-51FP66P-1/2/ 6d3587c5738f913b89f7e40ea647bdfd doi: 10.1016/j.jcf.2010.10.003 PMID: 21075062
22. Konstan MW, Geller DE, Minić P, Brockhaus F, Zhang J, Angyalosi G. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE trial. Pediatr Pulm. Wiley Subscription Services, Inc., A Wiley Company; 2010; 230-238. doi: 10.1002/ppul.21356
23. Barker AF, Couch L, Fiel SB, Gotfried MH, Ilowite J, Meyer KC, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med. American Thoracic SocietyNew York, NY; 2000; 162: 481-5. doi: 10.1164/ajrccm.162.2.9910086
24. Westerman EM, Le Brun PPH, Touw DJ, Frijlink HW, Heijerman HGM. Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study. J Cyst Fibros. 2004; 3: 23-28. Available: http://www.sciencedirect.com/science/article/pii/ S1569199303001255 PMID: 15463883
25. Bilton D, Henig N, Morrissey B, Gotfried M. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest. 2006; 130: 1503-10. doi: 10.1378/chest.130.5.1503 PMID: 17099030
26. Scheinberg P, Shore E. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest. 2005; 127: 1420-6. doi: 10.1378/chest.127.4.1420 PMID: 15821224
27. Newhouse MT, Hirst PH, Duddu SP, Walter YH, Tarara TE, Clark AR, et al. Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers. Chest. American College of Chest Physicians; 2003; 124: 360-366. doi: 10.1378/chest.124.1.360
28. Patton JS, Brain JD, Davies LA, Fiegel J, Gumbleton M, Kim K-J, et al. The particle has landed - characterizing the fate of inhaled pharmaceuticals. J Aerosol Med Pulm Drug Deliv. 2010; 23 Suppl 2: S71-87. doi: 10.1089/jamp.2010.0836 PMID: 21133802
29. Barker AF. Bronchiectasis. N Engl J Med. 2002; 346: 1383-1393. doi: 10.1056/NEJMra012519 PMID: 11986413
30. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. Blackwell Science Ltd; 2003; 56: 588-599. doi: 10.1046/j.1365-2125.2003.01892.x
31. Boiselle PM, Lynch D, editors. CT of the Airways. Humana Press; 2008. doi: 10.1007/978-1-59745-139-0
32. Alexander MR, Berglund EM, Kasik JE, Fox A, Chinn WM. The concentration of tobramycin in bronchial secretions. Chest. 1979; 75: 675-8. Available: http://www.ncbi.nlm.nih.gov/pubmed/374019 PMID: 374019
33. Panidis D, Markantonis SL, Boutzouka E, Karatzas S, Baltopoulos G. Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia. Chest. American College of Chest Physicians; 2005; 128: 545-52. doi: 10.1378/chest.128.2.545